Mineralys Therapeutics (MLYS) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 24.3% versus a loss of 40.3%. Mineralys Therapeutics is the larger company by market cap ($2.05 billion vs $1.91 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | XERS |
|---|---|---|
| Share price | $23.20 | $10.45 |
| Market cap | $2.05B | $1.91B |
| 1-day change | +3.66% | +2.55% |
| YTD return | -38.33% | +29.81% |
| 1-year return | -40.30% | +24.27% |
| 5-year return | — | +409.50% |
| Forward P/E | — | 28.24 |
| EPS (TTM) | $-4.22 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | $-154.65M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $47.65 | $11.33 |
| 52-week low | $21.46 | $5.25 |
| Distance from 52-week high | -51.31% | -7.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +109.05% | +23.06% |
| Average volume | 1.04M | 2.17M |
| Shares outstanding | 88.41M | 182.32M |
| Employees | 76 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed MLYS by 64.6 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
MLYS vs XERS FAQ
Which is bigger, Mineralys Therapeutics or Xeris Biopharma?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $2.05B compared with $1.91B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, MLYS or XERS?
XERS returned +24.27% over the past 12 months, compared with -40.30% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.